Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia

This study tests a combination of targeted drugs — venetoclax, dasatinib, prednisone, rituximab, and blinatumomab — for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), a type of leukemia with a specific genetic change that makes it harder to treat. The goal is to achieve deep remission without traditional intensive chemotherapy. **You may be eligible if...** - You have been diagnosed with Ph+ ALL or Ph+ mixed-phenotype acute leukemia confirmed by bone marrow biopsy - You are newly diagnosed (with no or minimal prior treatment) or your leukemia has relapsed - Your cancer cells express CD19 (especially if you have had prior CAR-T therapy) - You have not previously been treated with dasatinib (other TKI drugs are allowed) **You may NOT be eligible if...** - Your leukemia does not have the Philadelphia chromosome - You have previously received dasatinib - Your CD19 levels are too low (if you've had prior CAR-T therapy) - You have recently taken strong CYP3A-inhibiting medications and not waited the required washout period Talk to your doctor to see if this trial is right for you.